Camber Pharmaceuticals Launches Lurasidone Hydrochloride Tablets

Lurasidone Hydrochloride Tablets treat schizophrenia in adults and adolescents aged 13 to 17 years.
They address depressive episodes in Bipolar I Disorder for adults and pediatric patients aged 10 to 17.
Available strengths range from 20 mg to 120 mg, packaged in 30-count bottles.
Can be used as monotherapy or adjunctive therapy with lithium or valproate in adults.

Camber Pharmaceuticals is excited to announce the addition of Lurasidone Hydrochloride Tablets.

Lurasidone Hydrochloride Tablets are an atypical antipsychotic indicated for the treatment of:

Schizophrenia in adults and adolescents (13 to 17 years)
Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy
Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate

Lurasidone Hydrochloride Tablets in 20 mg, 40 mg, 60 mg, 80 mg, 120 mg strengths are available in 30-count bottles.

To find out more information on Lurasidone Hydrochloride Tablets, please visit: www.camberpharma.com/lurasidone

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.